Prova Education

Keeping Pace in Lung Cancer - HER2: Unveiling New Horizons in NSCLC Treatment

ReachMD Healthcare Image
RestartResume

Discover expert strategies for using FDA-approved targeted therapies to treat HER2-mutated NSCLC.

Available credits: 0.25

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Charu Aggarwal, MD, MPH
    Department of Medicine, Division of Hematology-Oncology
    University of Pennsylvania
    Perelman Center for Advanced Medicine
    Philadelphia, PA

    No relevant relationships reported at this time.

    Faculty:
    Jacob Sands, MD
    Thoracic Medical Oncologist
    Dana-Farber Cancer Institute
    Instructor of Medicine
    Harvard Medical School
    Boston, MA

    No relevant relationships reported at this time.

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Assess emerging clinical trial data and clinical trial data for patients with NSCLC and HER2 mutations
    • Describe current dosing regimens, monitoring and early identification of interstitial lung disease along with common and serious treatment related adverse events associated with treatment of NSCLC harboring HER2 mutations
  • Target Audience

    This activity is designed to meet the educational needs of community medical oncologists, oncology nurse practitioners, academic oncologists, pulmonologists, pathologists, physician assistants, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 11/15/2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25contact hours/0.025 CEUs of pharmacy contact hours.1 
     
    The Universal Activity Number for this program is JA0006235-0000-23-070-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Astra Zeneca and Daiichi Sankyo.

    The Keeping Pace in Lung Cancer educational series is supported by educational grants from Astra Zeneca, Daiichi Sankyo, and Johnson & Johnson.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this materialis not permitted without written permission from the copyright owner.  

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free